Active, not recruitingPhase 2NCT06620003
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Studying Marburg hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Albert B. Sabin Vaccine Institute
- Intervention
- cAd3-Marburg Vaccine(biological)
- Enrollment
- 200 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2026
Study locations (7)
- Optimal Research; LLC, Huntsville, Alabama, United States
- Synexus Clinical Research US, Inc., Phoenix, Arizona, United States
- Optimal Research; LLC, Melbourne, Florida, United States
- Synexus Clinical Research US, Inc., Chicago, Illinois, United States
- Optimal Research; LLC, Peoria, Illinois, United States
- Synexus Clinical Research US; Inc., Dallas, Texas, United States
- Synexus Clinical Research US, Inc., San Antonio, Texas, United States
Collaborators
Biomedical Advanced Research and Development Authority
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06620003 on ClinicalTrials.gov